Search

Your search keyword '"Yelensky, Roman"' showing total 550 results
Start Over Author "Yelensky, Roman"
550 results on '"Yelensky, Roman"'

1. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Author

Palmer, Christine D., Rappaport, Amy R., Davis, Matthew J., Hart, Meghan G., Scallan, Ciaran D., Hong, Sue-Jean, Gitlin, Leonid, Kraemer, Lauren D., Kounlavouth, Sonia, Yang, Aaron, Smith, Lindsey, Schenk, Desiree, Skoberne, Mojca, Taquechel, Kiara, Marrali, Martina, Jaroslavsky, Jason R., Nganje, Charmaine N., Maloney, Elizabeth, Zhou, Rita, Navarro-Gomez, Daniel, Greene, Adrienne C., Grotenbreg, Gijsbert, Greer, Renee, Blair, Wade, Cao, Minh Duc, Chan, Shawn, Bae, Kyounghwa, Spira, Alexander I., Roychowdhury, Sameek, Carbone, David P., Henick, Brian S., Drake, Charles G., Solomon, Benjamin J., Ahn, Daniel H., Mahipal, Amit, Maron, Steve B., Johnson, Benny, Rousseau, Raphael, Yelensky, Roman, Liao, Chih-Yi, Catenacci, Daniel V. T., Allen, Andrew, Ferguson, Andrew R., and Jooss, Karin

Published
2022
Full Text
View/download PDF

2. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Author

Swisher, Elizabeth M, Lin, Kevin K, Oza, Amit M, Scott, Clare L, Giordano, Heidi, Sun, James, Konecny, Gottfried E, Coleman, Robert L, Tinker, Anna V, O'Malley, David M, Kristeleit, Rebecca S, Ma, Ling, Bell-McGuinn, Katherine M, Brenton, James D, Cragun, Janiel M, Oaknin, Ana, Ray-Coquard, Isabelle, Harrell, Maria I, Mann, Elaina, Kaufmann, Scott H, Floquet, Anne, Leary, Alexandra, Harding, Thomas C, Goble, Sandra, Maloney, Lara, Isaacson, Jeff, Allen, Andrew R, Rolfe, Lindsey, Yelensky, Roman, Raponi, Mitch, and McNeish, Iain A

Subjects
Rare Diseases, Genetics, Cancer, Ovarian Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Aged, Antineoplastic Agents, BRCA1 Protein, BRCA2 Protein, Carcinoma, Ovarian Epithelial, Drug Resistance, Neoplasm, Fallopian Tube Neoplasms, Female, Follow-Up Studies, Germ-Line Mutation, Humans, Indoles, International Agencies, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Platinum, Poly(ADP-ribose) Polymerase Inhibitors, Poly(ADP-ribose) Polymerases, Prognosis, Prospective Studies, Salvage Therapy, Survival Rate, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundPoly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) mutations genomic loss of heterozygosity (LOH) might also represent homologous recombination deficiency. In ARIEL2, we assessed the ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor.MethodsARIEL2 is an international, multicentre, two-part, phase 2, open-label study done at 49 hospitals and cancer centres in Australia, Canada, France, Spain, the UK, and the USA. In ARIEL2 Part 1, patients with recurrent, platinum-sensitive, high-grade ovarian carcinoma were classified into one of three predefined homologous recombination deficiency subgroups on the basis of tumour mutational analysis: BRCA mutant (deleterious germline or somatic), BRCA wild-type and LOH high (LOH high group), or BRCA wild-type and LOH low (LOH low group). We prespecified a cutoff of 14% or more genomic LOH for LOH high. Patients began treatment with oral rucaparib at 600 mg twice per day for continuous 28 day cycles until disease progression or any other reason for discontinuation. The primary endpoint was progression-free survival. All patients treated with at least one dose of rucaparib were included in the safety analyses and all treated patients who were classified were included in the primary endpoint analysis. This trial is registered with ClinicalTrials.gov, number NCT01891344. Enrolment into ARIEL2 Part 1 is complete, although an extension (Part 2) is ongoing.Findings256 patients were screened and 206 were enrolled between Oct 30, 2013, and Dec 19, 2014. At the data cutoff date (Jan 18, 2016), 204 patients had received rucaparib, with 28 patients remaining in the study. 192 patients could be classified into one of the three predefined homologous recombination deficiency subgroups: BRCA mutant (n=40), LOH high (n=82), or LOH low (n=70). Tumours from 12 patients were established as BRCA wild-type, but could not be classified for LOH, because of insufficient neoplastic nuclei in the sample. The median duration of treatment for the 204 patients was 5·7 months (IQR 2·8-10·1). 24 patients in the BRCA mutant subgroup, 56 patients in the LOH high subgroup, and 59 patients in the LOH low subgroup had disease progression or died. Median progression-free survival after rucaparib treatment was 12·8 months (95% CI 9·0-14·7) in the BRCA mutant subgroup, 5·7 months (5·3-7·6) in the LOH high subgroup, and 5·2 months (3·6-5·5) in the LOH low subgroup. Progression-free survival was significantly longer in the BRCA mutant (hazard ratio 0·27, 95% CI 0·16-0·44, p

Published
2017

3. Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

Author

Wheler, Jennifer J, Atkins, Johnique T, Janku, Filip, Moulder, Stacy L, Stephens, Philip J, Yelensky, Roman, Valero, Vicente, Miller, Vincent, Kurzrock, Razelle, and Meric-Bernstam, Funda

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Breast Cancer, Biotechnology, Pediatric Research Initiative, Good Health and Well Being, FGFR, PI3K, breast cancer, next-generation sequencing
Abstract

There is limited data on co-expression of FGFR/FGR amplifications and PI3K/ AKT/mTOR alterations in breast cancer. Tumors from patients with metastatic breast cancer referred to our Phase I Program were analyzed by next generation sequencing (NGS). Genomic libraries were selected for all exons of 236 (or 182) cancer-related genes sequenced to average depth of >500× in a CLIA laboratory (Foundation Medicine, Cambridge, MA, USA) and analyzed for all classes of genomic alterations. We report genomic profiles of 112 patients with metastatic breast cancer, median age 55 years (range, 27-78). Twenty-four patients (21%) had at least one amplified FGFR or FGF. Fifteen of the 24 patients (63%) also had an alteration in the PI3K/ AKT/mTOR pathway. There was no association between alterations in FGFR/FGF and PI3K/AKT/mTOR (P=0.49). Patients with simultaneous amplification in FGFR/FGF signaling and the PI3K/AKT/mTOR pathway had a higher rate of SD≥6 months/PR/ CR when treated with therapies targeting the PI3K/AKT/mTOR pathway than patients with only alterations in the PI3K/AKT/mTOR pathway (73% vs. 34%; P=0.0376) and remained on treatment longer (6.8 vs. 3.7 months; P=0.053). Higher response rates were seen in patients with simultaneous amplification in FGFR/FGF signaling and alterations in the PI3K/AKT/mTOR pathway who were treated with inhibitors of that pathway.

Published
2016

4. Multiple gene aberrations and breast cancer: lessons from super-responders

Author

Wheler, Jennifer J, Atkins, Johnique T, Janku, Filip, Moulder, Stacy L, Yelensky, Roman, Stephens, Philip J, and Kurzrock, Razelle

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Human Genome, Cancer, Breast Cancer, Biotechnology, Genetics, Adult, Anastrozole, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Class I Phosphatidylinositol 3-Kinases, Disease-Free Survival, Everolimus, Female, Gene Expression Regulation, Neoplastic, High-Throughput Nucleotide Sequencing, Humans, Middle Aged, Mutation, Neoplasm Proteins, Nitriles, Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases, Treatment Outcome, Triazoles, Breast cancer, Genomic aberrations, Next generation sequencing, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BackgroundThe presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.Case presentationsWe performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone therapy-refractory breast cancer, who achieved partial or complete responses when treated with anastrozole and everolimus. Tumors were analyzed using a targeted next generation sequencing (NGS) assay in a Clinical Laboratory Improvement Amendments laboratory. Genomic libraries were captured for 3,230 exons in 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to high coverage. Patients received anastrozole (1 g PO daily) and everolimus (5 or 10 mg PO daily). Thirty-two patients with breast cancer were treated on study and 5 (16 %) achieved a partial or complete response. Primary breast tissue was available for NGS testing in three of the responders (partial response with progression free survival of 11 and 14 months, respectively; complete response with progression free survival of 9+ months). The following molecular aberrations were observed: PTEN loss by immunohistochemistry, CCDN1 and FGFR1 amplifications, and PRKDC re-arrangement (NGS) (patient #1); PIK3CA and PIK3R1 mutations, and CCDN1, FGFR1, MYC amplifications (patient #2); TP53 mutation, CCNE1, IRS2 and MCL1 amplifications (patient #3). Some (but not all) of these aberrations converge on the PI3K/AKT/mTOR pathway, perhaps accounting for response.ConclusionsPatients with estrogen receptor-positive breast cancer can achieve significant responses on a combination of anastrozole and everolimus, even in the presence of multiple molecular aberrations. Further study of next generation sequencing-profiled tumors for convergence and resistance pathways is warranted.

Published
2015

5. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

Author

Wheler, Jennifer, Yelensky, Roman, Falchook, Gerald, Kim, Kevin B, Hwu, Patrick, Tsimberidou, Apostolia M, Stephens, Philip J, Hong, David, Cronin, Maureen T, and Kurzrock, Razelle

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Clinical Research, Human Genome, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Adult, Drug Resistance, Neoplasm, Female, High-Throughput Nucleotide Sequencing, Humans, Male, Melanoma, Middle Aged, Mutation, Pilot Projects, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Treatment Outcome, Young Adult, BRAF mutation, Next generation sequencing, Resistance, Time to treatment failure, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Epidemiology
Abstract

BackgroundPatients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance.MethodsTumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial response (PR) or complete response (CR) on BRAF and/or MEK inhibitors was analyzed using next generation sequencing (NGS) assay. Genomic libraries were captured for 3230 exons in 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to average median depth of 734X with 99% of bases covered >100X.ResultsThree of the ten patients (median number of prior therapies = 2) attained prolonged CR (duration = 23.6+ to 28.7+ months); seven patients achieved either a PR or a short-lived CR. One patient who achieved CR ongoing at 28.7+ months and had tissue available close to the time of initiating BRAF inhibitor therapy had only a BRAF mutation. Abnormalities in addition to BRAF mutation found in other patients included: mutations in NRAS, APC and NF1; amplifications in BRAF, aurora kinase A, MYC, MITF and MET; deletions in CDKN2A/B and PAX5; and, alterations in RB1 and ATM. Heterogeneity between patients and molecular evolution within patients was noted.ConclusionNGS identified potentially actionable DNA alterations that could account for resistance in patients with BRAF mutation-positive advanced melanoma who achieved a PR or CR but whose tumors later progressed. A subset of patients with advanced melanoma may harbor only a BRAF mutation and achieve a durable CR on BRAF pathway inhibitors.

Published
2015

6. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

Author

Wheler, Jennifer J, Moulder, Stacy L, Naing, Aung, Janku, Filip, Piha-Paul, Sarina A, Falchook, Gerald S, Zinner, Ralph, Tsimberidou, Apostolia M, Fu, Siqing, Hong, David S, Atkins, Johnique T, Yelensky, Roman, Stephens, Philip J, and Kurzrock, Razelle

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Anastrozole, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Everolimus, Female, Genital Neoplasms, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Nitriles, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction, Sirolimus, TOR Serine-Threonine Kinases, Treatment Outcome, Triazoles, Young Adult, Gynecologic Cancer, Hormone therapy, Oncology and carcinogenesis
Abstract

BackgroundSince PI3K/AKT/mTOR pathway activation diminishes the effects of hormone therapy, combining aromatase inhibitors (anatrozole) with mTOR inhibitors (everolimus) was investigated.Patients and methodsWe evaluated anastrozole and everolimus in 55 patients with metastatic estrogen (ER) and/or progesterone receptor (PR)-positive breast and gynecologic tumors. Endpoints were safety, antitumor activity and molecular correlates.ResultsFull doses of anastrozole (1 mg PO daily) and everolimus (10 mg PO daily) were well tolerated. Twelve of 50 evaluable patients (24%) (median = 3 prior therapies) achieved stable disease (SD) ≥ 6 months/partial response (PR)/complete response (CR) (n = 5 (10%) with PR/CR): 9 of 32 (28%) with breast cancer (n=5 (16%) with PR/CR); 2 of 10 (20%), ovarian cancer; and 1 of 6 (17%), endometrial cancer. Six of 22 patients (27%) with molecular alterations in the PI3K/AKT/mTOR pathway achieved SD ≥ 6 months/PR/CR. Six of 8 patients (75%) with SD ≥ 6 months/PR/CR with molecular testing demonstrated at least one alteration in the PI3K/AKT/mTOR pathway: mutations in PIK3CA (n=3) and AKT1 (n=1) or PTEN loss (n=3). All three responders (CR (n = 1); PR (n=2)) who had next generation sequencing demonstrated additional alterations: amplifications in CCNE1, IRS2, MCL1, CCND1, FGFR1 and MYC and a rearrangement in PRKDC.ConclusionsCombination anastrozole and everolimus is well tolerated at full approved doses, and is active in heavily-pretreated patients with ER and/or PR-positive breast, ovarian and endometrial cancers. Responses were observed in patients with multiple molecular aberrations. CLINICAL TRAILS INCLUDED: NCT01197170.

Published
2014

7. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms

Author

Wheler, Jennifer J, Parker, Barbara A, Lee, Jack J, Atkins, Johnique T, Janku, Filip, Tsimberidou, Apostolia M, Zinner, Ralph, Subbiah, Vivek, Fu, Siqing, Schwab, Richard, Moulder, Stacy, Valero, Vicente, Schwaederle, Maria, Yelensky, Roman, Miller, Vincent A, Stephens, M Philip J, Meric-Bernstam, Funda, and Kurzrock, Razelle

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Breast Cancer, Genetics, Good Health and Well Being, Antineoplastic Agents, Breast Neoplasms, Female, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Humans, Molecular Targeted Therapy, Neoplasm Proteins, Genomics, PI3K, Clinical Trials, Oncology and carcinogenesis
Abstract

Our analysis of the tumors of 57 women with metastatic breast cancer with next generation sequencing (NGS) demonstrates that each patient's tumor is unique in its molecular fingerprint. We observed 216 somatic aberrations in 70 different genes, including 131 distinct aberrations. The most common gene alterations (in order of decreasing frequency) included: TP53, PIK3CA, CCND1, MYC, HER2 (ERBB2), MCL1, PTEN, FGFR1, GATA3, NF1, PIK3R1, BRCA2, EGFR, IRS2, CDH1, CDKN2A, FGF19, FGF3 and FGF4. Aberrations included mutations (46%), amplifications (45%), deletions (5%), splices (2%), truncations (1%), fusions (0.5%) and rearrangements (0.5%), with multiple distinct variants within the same gene. Many of these aberrations represent druggable targets, either through direct pathway inhibition or through an associated pathway (via 'crosstalk'). The 'molecular individuality' of these tumors suggests that a customized strategy, using an "N-of-One" model of precision medicine, may represent an optimal approach for the treatment of patients with advanced tumors.

Published
2014

8. Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M, Giltnane, Jennifer M, Wang, Kai, Schwarz, Luis J, Young, Christian D, Cook, Rebecca S, Owens, Phillip, Sanders, Melinda E, Kuba, Maria G, Sánchez, Violeta, Kurupi, Richard, Moore, Preston D, Pinto, Joseph A, Doimi, Franco D, Gómez, Henry, Horiuchi, Dai, Goga, Andrei, Lehmann, Brian D, Bauer, Joshua A, Pietenpol, Jennifer A, Ross, Jeffrey S, Palmer, Gary A, Yelensky, Roman, Cronin, Maureen, Miller, Vincent A, Stephens, Phillip J, and Arteaga, Carlos L

Subjects
Biotechnology, Human Genome, Breast Cancer, Clinical Research, Genetics, Cancer, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Cluster Analysis, DNA Copy Number Variations, Drug Resistance, Neoplasm, Female, Gene Amplification, Gene Expression Profiling, Genes, myc, Humans, Ki-67 Antigen, Myeloid Cell Leukemia Sequence 1 Protein, Neoadjuvant Therapy, Neoplasm, Residual, Prognosis, Treatment Outcome, Triple Negative Breast Neoplasms, Oncology and Carcinogenesis
Abstract

UnlabelledNeoadjuvant chemotherapy (NAC) induces a pathologic complete response (pCR) in approximately 30% of patients with triple-negative breast cancers (TNBC). In patients lacking a pCR, NAC selects a subpopulation of chemotherapy-resistant tumor cells. To understand the molecular underpinnings driving treatment-resistant TNBCs, we performed comprehensive molecular analyses on the residual disease of 74 clinically defined TNBCs after NAC, including next-generation sequencing (NGS) on 20 matched pretreatment biopsies. Combined NGS and digital RNA expression analysis identified diverse molecular lesions and pathway activation in drug-resistant tumor cells. Ninety percent of the tumors contained a genetic alteration potentially treatable with a currently available targeted therapy. Thus, profiling residual TNBCs after NAC identifies targetable molecular lesions in the chemotherapy-resistant component of the tumor, which may mirror micrometastases destined to recur clinically. These data can guide biomarker-driven adjuvant studies targeting these micrometastases to improve the outcome of patients with TNBC who do not respond completely to NAC.SignificanceThis study demonstrates the spectrum of genomic alterations present in residual TNBC after NAC. Because TNBCs that do not achieve a CR after NAC are likely to recur as metastatic disease at variable times after surgery, these alterations may guide the selection of targeted therapies immediately after mastectomy before these metastases become evident.

Published
2014

9. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

Author

Wiesner, Thomas, He, Jie, Yelensky, Roman, Esteve-Puig, Rosaura, Botton, Thomas, Yeh, Iwei, Lipson, Doron, Otto, Geoff, Brennan, Kristina, Murali, Rajmohan, Garrido, Maria, Miller, Vincent A, Ross, Jeffrey S, Berger, Michael F, Sparatta, Alyssa, Palmedo, Gabriele, Cerroni, Lorenzo, Busam, Klaus J, Kutzner, Heinz, Cronin, Maureen T, Stephens, Philip J, and Bastian, Boris C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Base Sequence, DNA Mutational Analysis, Genome, Human, Humans, Melanoma, Molecular Sequence Data, Nevus, Epithelioid and Spindle Cell, Oncogene Proteins, Fusion, Protein Kinases, Reproducibility of Results, Skin Neoplasms, Xenograft Model Antitumor Assays
Abstract

Spitzoid neoplasms are a group of melanocytic tumours with distinctive histopathological features. They include benign tumours (Spitz naevi), malignant tumours (spitzoid melanomas) and tumours with borderline histopathological features and uncertain clinical outcome (atypical Spitz tumours). Their genetic underpinnings are poorly understood, and alterations in common melanoma-associated oncogenes are typically absent. Here we show that spitzoid neoplasms harbour kinase fusions of ROS1 (17%), NTRK1 (16%), ALK (10%), BRAF (5%) and RET (3%) in a mutually exclusive pattern. The chimeric proteins are constitutively active, stimulate oncogenic signalling pathways, are tumourigenic and are found in the entire biologic spectrum of spitzoid neoplasms, including 55% of Spitz naevi, 56% of atypical Spitz tumours and 39% of spitzoid melanomas. Kinase inhibitors suppress the oncogenic signalling of the fusion proteins in vitro. In summary, kinase fusions account for the majority of oncogenic aberrations in spitzoid neoplasms and may serve as therapeutic targets for metastatic spitzoid melanomas.

Published
2014

11. Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

Author

Bulik-Sullivan, Brendan, Busby, Jennifer, Palmer, Christine D, Davis, Matthew J, Murphy, Tyler, Clark, Andrew, Busby, Michele, Duke, Fujiko, Yang, Aaron, Young, Lauren, Ojo, Noelle C, Caldwell, Kamilah, Abhyankar, Jesse, Boucher, Thomas, Hart, Meghan G, Makarov, Vladimir, De Montpreville, Vincent Thomas, Mercier, Olaf, Chan, Timothy A, Scagliotti, Giorgio, Bironzo, Paolo, Novello, Silvia, Karachaliou, Niki, Rosell, Rafael, Anderson, Ian, Gabrail, Nashat, Hrom, John, Limvarapuss, Chainarong, Choquette, Karin, Spira, Alexander, Rousseau, Raphael, Voong, Cynthia, Rizvi, Naiyer A, Fadel, Elie, Frattini, Mark, Jooss, Karin, Skoberne, Mojca, Francis, Joshua, and Yelensky, Roman

Published
2019
Full Text
View/download PDF

12. Data from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

Author

Chmielecki, Juliann, primary, Hutchinson, Katherine E., primary, Frampton, Garrett M., primary, Chalmers, Zachary R., primary, Johnson, Adrienne, primary, Shi, Chanjuan, primary, Elvin, Julia, primary, Ali, Siraj M., primary, Ross, Jeffrey S., primary, Basturk, Olca, primary, Balasubramanian, Sohail, primary, Lipson, Doron, primary, Yelensky, Roman, primary, Pao, William, primary, Miller, Vincent A., primary, Klimstra, David S., primary, and Stephens, Philip J., primary

Published
2023
Full Text
View/download PDF

13. Data from RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

Author

Cheng, Haiying, primary, Zou, Yiyu, primary, Ross, Jeffrey S., primary, Wang, Kai, primary, Liu, Xuewen, primary, Halmos, Balazs, primary, Ali, Siraj M., primary, Liu, Huijie, primary, Verma, Amit, primary, Montagna, Cristina, primary, Chachoua, Abraham, primary, Goel, Sanjay, primary, Schwartz, Edward L., primary, Zhu, Changcheng, primary, Shan, Jidong, primary, Yu, Yiting, primary, Gritsman, Kira, primary, Yelensky, Roman, primary, Lipson, Doron, primary, Otto, Geoff, primary, Hawryluk, Matthew, primary, Stephens, Philip J., primary, Miller, Vincent A., primary, Piperdi, Bilal, primary, and Perez-Soler, Roman, primary

Published
2023
Full Text
View/download PDF

14. Data from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

15. Data from Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents

Author

Ganesan, Prasanth, primary, Moulder, Stacy, primary, Lee, J. Jack, primary, Janku, Filip, primary, Valero, Vicente, primary, Zinner, Ralph G., primary, Naing, Aung, primary, Fu, Siqing, primary, Tsimberidou, Apostolia M., primary, Hong, David, primary, Stephen, Bettzy, primary, Stephens, Philip, primary, Yelensky, Roman, primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Wheler, Jennifer J., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Methods from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

Author

Chmielecki, Juliann, primary, Hutchinson, Katherine E., primary, Frampton, Garrett M., primary, Chalmers, Zachary R., primary, Johnson, Adrienne, primary, Shi, Chanjuan, primary, Elvin, Julia, primary, Ali, Siraj M., primary, Ross, Jeffrey S., primary, Basturk, Olca, primary, Balasubramanian, Sohail, primary, Lipson, Doron, primary, Yelensky, Roman, primary, Pao, William, primary, Miller, Vincent A., primary, Klimstra, David S., primary, and Stephens, Philip J., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table S3 from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

Author

Chmielecki, Juliann, primary, Hutchinson, Katherine E., primary, Frampton, Garrett M., primary, Chalmers, Zachary R., primary, Johnson, Adrienne, primary, Shi, Chanjuan, primary, Elvin, Julia, primary, Ali, Siraj M., primary, Ross, Jeffrey S., primary, Basturk, Olca, primary, Balasubramanian, Sohail, primary, Lipson, Doron, primary, Yelensky, Roman, primary, Pao, William, primary, Miller, Vincent A., primary, Klimstra, David S., primary, and Stephens, Philip J., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table S2 from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Author

Frampton, Garrett M., primary, Ali, Siraj M., primary, Rosenzweig, Mark, primary, Chmielecki, Juliann, primary, Lu, Xinyuan, primary, Bauer, Todd M., primary, Akimov, Mikhail, primary, Bufill, Jose A., primary, Lee, Carrie, primary, Jentz, David, primary, Hoover, Rick, primary, Ou, Sai-Hong Ignatius, primary, Salgia, Ravi, primary, Brennan, Tim, primary, Chalmers, Zachary R., primary, Jaeger, Savina, primary, Huang, Alan, primary, Elvin, Julia A., primary, Erlich, Rachel, primary, Fichtenholtz, Alex, primary, Gowen, Kyle A., primary, Greenbowe, Joel, primary, Johnson, Adrienne, primary, Khaira, Depinder, primary, McMahon, Caitlin, primary, Sanford, Eric M., primary, Roels, Steven, primary, White, Jared, primary, Greshock, Joel, primary, Schlegel, Robert, primary, Lipson, Doron, primary, Yelensky, Roman, primary, Morosini, Deborah, primary, Ross, Jeffrey S., primary, Collisson, Eric, primary, Peters, Malte, primary, Stephens, Philip J., primary, and Miller, Vincent A., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data Figure 5 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

20. Data from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table S1 from TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

Author

Wheler, Jennifer J., primary, Janku, Filip, primary, Naing, Aung, primary, Li, Yali, primary, Stephen, Bettzy, primary, Zinner, Ralph, primary, Subbiah, Vivek, primary, Fu, Siqing, primary, Karp, Daniel, primary, Falchook, Gerald S., primary, Tsimberidou, Apostolia M., primary, Piha-Paul, Sarina, primary, Anderson, Roosevelt, primary, Ke, Danxia, primary, Miller, Vincent, primary, Yelensky, Roman, primary, Lee, J. Jack, primary, Hong, David, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure S2 from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

Author

Chmielecki, Juliann, primary, Hutchinson, Katherine E., primary, Frampton, Garrett M., primary, Chalmers, Zachary R., primary, Johnson, Adrienne, primary, Shi, Chanjuan, primary, Elvin, Julia, primary, Ali, Siraj M., primary, Ross, Jeffrey S., primary, Basturk, Olca, primary, Balasubramanian, Sohail, primary, Lipson, Doron, primary, Yelensky, Roman, primary, Pao, William, primary, Miller, Vincent A., primary, Klimstra, David S., primary, and Stephens, Philip J., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 4 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 5 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data Tables from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 1 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Data Figure 6 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data Figure 7 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Data Figure 2 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table S1A - S1B from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

Author

Chmielecki, Juliann, primary, Hutchinson, Katherine E., primary, Frampton, Garrett M., primary, Chalmers, Zachary R., primary, Johnson, Adrienne, primary, Shi, Chanjuan, primary, Elvin, Julia, primary, Ali, Siraj M., primary, Ross, Jeffrey S., primary, Basturk, Olca, primary, Balasubramanian, Sohail, primary, Lipson, Doron, primary, Yelensky, Roman, primary, Pao, William, primary, Miller, Vincent A., primary, Klimstra, David S., primary, and Stephens, Philip J., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data Figure 4 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table S1 from Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents

Author

Ganesan, Prasanth, primary, Moulder, Stacy, primary, Lee, J. Jack, primary, Janku, Filip, primary, Valero, Vicente, primary, Zinner, Ralph G., primary, Naing, Aung, primary, Fu, Siqing, primary, Tsimberidou, Apostolia M., primary, Hong, David, primary, Stephen, Bettzy, primary, Stephens, Philip, primary, Yelensky, Roman, primary, Meric-Bernstam, Funda, primary, Kurzrock, Razelle, primary, and Wheler, Jennifer J., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data Figure Legends from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

35. Data from TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

Author

Wheler, Jennifer J., primary, Janku, Filip, primary, Naing, Aung, primary, Li, Yali, primary, Stephen, Bettzy, primary, Zinner, Ralph, primary, Subbiah, Vivek, primary, Fu, Siqing, primary, Karp, Daniel, primary, Falchook, Gerald S., primary, Tsimberidou, Apostolia M., primary, Piha-Paul, Sarina, primary, Anderson, Roosevelt, primary, Ke, Danxia, primary, Miller, Vincent, primary, Yelensky, Roman, primary, Lee, J. Jack, primary, Hong, David, primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

36. Data from Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Author

Frampton, Garrett M., primary, Ali, Siraj M., primary, Rosenzweig, Mark, primary, Chmielecki, Juliann, primary, Lu, Xinyuan, primary, Bauer, Todd M., primary, Akimov, Mikhail, primary, Bufill, Jose A., primary, Lee, Carrie, primary, Jentz, David, primary, Hoover, Rick, primary, Ou, Sai-Hong Ignatius, primary, Salgia, Ravi, primary, Brennan, Tim, primary, Chalmers, Zachary R., primary, Jaeger, Savina, primary, Huang, Alan, primary, Elvin, Julia A., primary, Erlich, Rachel, primary, Fichtenholtz, Alex, primary, Gowen, Kyle A., primary, Greenbowe, Joel, primary, Johnson, Adrienne, primary, Khaira, Depinder, primary, McMahon, Caitlin, primary, Sanford, Eric M., primary, Roels, Steven, primary, White, Jared, primary, Greshock, Joel, primary, Schlegel, Robert, primary, Lipson, Doron, primary, Yelensky, Roman, primary, Morosini, Deborah, primary, Ross, Jeffrey S., primary, Collisson, Eric, primary, Peters, Malte, primary, Stephens, Philip J., primary, and Miller, Vincent A., primary

Published
2023
Full Text
View/download PDF

37. Suplpementary Table 2 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figures 1 - 3 from RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors

Author

Cheng, Haiying, primary, Zou, Yiyu, primary, Ross, Jeffrey S., primary, Wang, Kai, primary, Liu, Xuewen, primary, Halmos, Balazs, primary, Ali, Siraj M., primary, Liu, Huijie, primary, Verma, Amit, primary, Montagna, Cristina, primary, Chachoua, Abraham, primary, Goel, Sanjay, primary, Schwartz, Edward L., primary, Zhu, Changcheng, primary, Shan, Jidong, primary, Yu, Yiting, primary, Gritsman, Kira, primary, Yelensky, Roman, primary, Lipson, Doron, primary, Otto, Geoff, primary, Hawryluk, Matthew, primary, Stephens, Philip J., primary, Miller, Vincent A., primary, Piperdi, Bilal, primary, and Perez-Soler, Roman, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data Figure 3 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Data Figure 1 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

Author

Balko, Justin M., primary, Giltnane, Jennifer M., primary, Wang, Kai, primary, Schwarz, Luis J., primary, Young, Christian D., primary, Cook, Rebecca S., primary, Owens, Phillip, primary, Sanders, Melinda E., primary, Kuba, Maria G., primary, Sánchez, Violeta, primary, Kurupi, Richard, primary, Moore, Preston D., primary, Pinto, Joseph A., primary, Doimi, Franco D., primary, Gómez, Henry, primary, Horiuchi, Dai, primary, Goga, Andrei, primary, Lehmann, Brian D., primary, Bauer, Joshua A., primary, Pietenpol, Jennifer A., primary, Ross, Jeffrey S., primary, Palmer, Gary A., primary, Yelensky, Roman, primary, Cronin, Maureen, primary, Miller, Vincent A., primary, Stephens, Phillip J., primary, and Arteaga, Carlos L., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 3 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

Author

Meric-Bernstam, Funda, primary, Frampton, Garrett M., primary, Ferrer-Lozano, Jaime, primary, Yelensky, Roman, primary, Pérez-Fidalgo, Jose A., primary, Wang, Ying, primary, Palmer, Gary A., primary, Ross, Jeffrey S., primary, Miller, Vincent A., primary, Su, Xiaoping, primary, Eroles, Pilar, primary, Barrera, Juan Antonio, primary, Burgues, Octavio, primary, Lluch, Ana M., primary, Zheng, Xiaofeng, primary, Sahin, Aysegul, primary, Stephens, Philip J., primary, Mills, Gordon B., primary, Cronin, Maureen T., primary, and Gonzalez-Angulo, Ana M., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Patient Data from Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

Author

Jeselsohn, Rinath, primary, Yelensky, Roman, primary, Buchwalter, Gilles, primary, Frampton, Garrett, primary, Meric-Bernstam, Funda, primary, Gonzalez-Angulo, Ana Maria, primary, Ferrer-Lozano, Jaime, primary, Perez-Fidalgo, Jose A., primary, Cristofanilli, Massimo, primary, Gómez, Henry, primary, Arteaga, Carlos L., primary, Giltnane, Jennifer, primary, Balko, Justin M., primary, Cronin, Maureen T., primary, Jarosz, Mirna, primary, Sun, James, primary, Hawryluk, Matthew, primary, Lipson, Doron, primary, Otto, Geoff, primary, Ross, Jeffrey S., primary, Dvir, Addie, primary, Soussan-Gutman, Lior, primary, Wolf, Ido, primary, Rubinek, Tamar, primary, Gilmore, Lauren, primary, Schnitt, Stuart, primary, Come, Steven E., primary, Pusztai, Lajos, primary, Stephens, Philip, primary, Brown, Myles, primary, and Miller, Vincent A., primary

Published
2023
Full Text
View/download PDF

43. Supplemental table 1 from Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

Author

Wang, Kai, primary, Russell, Jeffery S., primary, McDermott, Jessica D., primary, Elvin, Julia A., primary, Khaira, Depinder, primary, Johnson, Adrienne, primary, Jennings, Timothy A., primary, Ali, Siraj M., primary, Murray, Molly, primary, Marshall, Carrie, primary, Oldham, Dwight S., primary, Washburn, Donna, primary, Wong, Stuart J., primary, Chmielecki, Juliann, primary, Yelensky, Roman, primary, Lipson, Doron, primary, Miller, Vincent A., primary, Stephens, Philip J., primary, Serracino, Hilary S., primary, Ross, Jeffrey S., primary, and Bowles, Daniel W., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 1 from A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

Author

Ross, Jeffrey S., primary, Wang, Kai, primary, Gay, Laurie M., primary, Al-Rohil, Rami N., primary, Nazeer, Tipu, primary, Sheehan, Christine E., primary, Jennings, Timothy A., primary, Otto, Geoff A., primary, Donahue, Amy, primary, He, Jie, primary, Palmer, Gary, primary, Ali, Siraj, primary, Nahas, Michelle, primary, Young, Geneva, primary, LaBrecque, Elaine, primary, Frampton, Garrett, primary, Erlich, Rachel, primary, Curran, John A., primary, Brennan, Kristina, primary, Downing, Sean R., primary, Yelensky, Roman, primary, Lipson, Doron, primary, Hawryluk, Matthew, primary, Miller, Vincent A., primary, and Stephens, Philip J., primary

Published
2023
Full Text
View/download PDF

45. Data from Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Author

Wheler, Jennifer J., primary, Janku, Filip, primary, Naing, Aung, primary, Li, Yali, primary, Stephen, Bettzy, primary, Zinner, Ralph, primary, Subbiah, Vivek, primary, Fu, Siqing, primary, Karp, Daniel, primary, Falchook, Gerald S., primary, Tsimberidou, Apostolia M., primary, Piha-Paul, Sarina, primary, Anderson, Roosevelt, primary, Ke, Danxia, primary, Miller, Vincent, primary, Yelensky, Roman, primary, Lee, J. Jack, primary, Hong, David S., primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table S1: from Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Author

Wheler, Jennifer J., primary, Janku, Filip, primary, Naing, Aung, primary, Li, Yali, primary, Stephen, Bettzy, primary, Zinner, Ralph, primary, Subbiah, Vivek, primary, Fu, Siqing, primary, Karp, Daniel, primary, Falchook, Gerald S., primary, Tsimberidou, Apostolia M., primary, Piha-Paul, Sarina, primary, Anderson, Roosevelt, primary, Ke, Danxia, primary, Miller, Vincent, primary, Yelensky, Roman, primary, Lee, J. Jack, primary, Hong, David S., primary, and Kurzrock, Razelle, primary

Published
2023
Full Text
View/download PDF

47. Supplemental Figures from RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Author

Loi, Sherene, primary, Dushyanthen, Sathana, primary, Beavis, Paul A., primary, Salgado, Roberto, primary, Denkert, Carsten, primary, Savas, Peter, primary, Combs, Susan, primary, Rimm, David L., primary, Giltnane, Jennifer M., primary, Estrada, Monica V., primary, Sánchez, Violeta, primary, Sanders, Melinda E., primary, Cook, Rebecca S., primary, Pilkinton, Mark A., primary, Mallal, Simon A., primary, Wang, Kai, primary, Miller, Vincent A., primary, Stephens, Phil J., primary, Yelensky, Roman, primary, Doimi, Franco D., primary, Gómez, Henry, primary, Ryzhov, Sergey V., primary, Darcy, Phillip K., primary, Arteaga, Carlos L., primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Table S1. from Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

Author

Ross, Jeffrey S., primary, Wang, Kai, primary, Sheehan, Christine E., primary, Boguniewicz, Ann B., primary, Otto, Geoff, primary, Downing, Sean R., primary, Sun, James, primary, He, Jie, primary, Curran, John A., primary, Ali, Siraj, primary, Yelensky, Roman, primary, Lipson, Doron, primary, Palmer, Gary, primary, Miller, Vincent A., primary, and Stephens, Philip J., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Data from Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

Author

Ross, Jeffrey S., primary, Wang, Kai, primary, Sheehan, Christine E., primary, Boguniewicz, Ann B., primary, Otto, Geoff, primary, Downing, Sean R., primary, Sun, James, primary, He, Jie, primary, Curran, John A., primary, Ali, Siraj, primary, Yelensky, Roman, primary, Lipson, Doron, primary, Palmer, Gary, primary, Miller, Vincent A., primary, and Stephens, Philip J., primary

Published
2023
Full Text
View/download PDF

50. Supplementary figure legend from RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Author

Loi, Sherene, primary, Dushyanthen, Sathana, primary, Beavis, Paul A., primary, Salgado, Roberto, primary, Denkert, Carsten, primary, Savas, Peter, primary, Combs, Susan, primary, Rimm, David L., primary, Giltnane, Jennifer M., primary, Estrada, Monica V., primary, Sánchez, Violeta, primary, Sanders, Melinda E., primary, Cook, Rebecca S., primary, Pilkinton, Mark A., primary, Mallal, Simon A., primary, Wang, Kai, primary, Miller, Vincent A., primary, Stephens, Phil J., primary, Yelensky, Roman, primary, Doimi, Franco D., primary, Gómez, Henry, primary, Ryzhov, Sergey V., primary, Darcy, Phillip K., primary, Arteaga, Carlos L., primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results